Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 28, 2005 Philip Durell	Tom Gardner Interviews Philip Durell Tom and the author get together to talk value investing.
The Motley Fool November 12, 2004 James Early	5 Stock Time Bombs Five stocks whose glory days may be numbered.
The Motley Fool January 13, 2004 Alyce Lomax	MedImmune's Sticker Shock Price cut for FluMist is reportedly in the works.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
The Motley Fool March 1, 2004 Alyce Lomax	MedImmune Under the Weather After short-term setbacks, the biotech turns to the long term.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool March 9, 2005 Brian Richards	The Bargain Hunter Value investments lurk in any market. The trick is knowing how to find them.
The Motley Fool June 16, 2004 Alyce Lomax	It's Half-Time at MedImmune The company will slash the price of FluMist.
The Motley Fool October 22, 2004 Rich Duprey	Chiron Reports Profit, But So What? The flu vaccine debacle overshadows the company's profits and earnings.
The Motley Fool March 29, 2005 Rick Aristotle Munarriz	New Life in Death Care Alderwoods Group continues to make money in the grim yet predictably steady funeral services business. Investors, take note.
The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
The Motley Fool October 5, 2004 Alyce Lomax	No Cheer for Chiron A U.K. regulatory body suspended its manufacturing license because of contamination. The company's misstep adds up to another rough flu season.
The Motley Fool November 8, 2004 Rich Duprey	A Stock From the Industry Side Out Keeping tabs on your company's industry can help energize your portfolio's returns.
Health October 2007 Sarah Clachar	Read this BEFORE you get a flu shot The flu vaccine may not be as good -- or as safe -- as you think.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool July 25, 2005 W.D. Crotty	Alderwoods Arises Funeral-care provider Alderwoods turns in a quarter that blows away the analyst estimate.
The Motley Fool July 19, 2005 Seth Jayson	Simple Ways to Whip the Experts Beating Wall Street is simple -- if you look for value.
BusinessWeek March 29, 2004 Gene G. Marcial	Recovery At MedImmune? Flu season is over, but it was a disaster for the No. 6 U.S. biotech, MedImmune (MEDI ). Its ballyhooed FluMist, a nasal-spray flu vaccine, was a flop -- which sent the stock reeling, from 42 in June to 23 now. As a result, some pros are buying: David Katz of Matrix Asset Advisors is confident MedImmune can turn FluMist around, by pricing it lower and educating doctors and consumers about the product.
The Motley Fool December 30, 2004 Rich Duprey	Alderwoods Buries Stiff Competition The funeral services provider still represents a good value in a competitive industry. An investment in Alderwoods is not like one in your typical growth stock.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
The Motley Fool September 8, 2004 James Early	3 Stocks Worth Watching Here are a few tactics for finding the hidden gems of the market, along with three companies to watch.
The Motley Fool February 23, 2005 James Early	Time to Invest Getting a handle on your portfolio begins with getting a handle on your time. Time is the undiscussed bane of the investor, forcing shortcuts, compromises, and outright gambles into what should be a calculated, methodical process.
The Motley Fool October 6, 2004 Rich Duprey	Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices.
The Motley Fool May 19, 2004 Paul Elliott	The Art of Picking Winners The author explores Hidden Gems stock selection.
The Motley Fool May 18, 2004 Selena Maranjian	Places for Great Investment Ideas There are some good investment newsletters out there, even from us.
The Motley Fool August 19, 2004 Rich Duprey	Can Costco Grow With Death? The discounter's entry could change the face of the funeral industry.
The Motley Fool February 16, 2006 Jim Mueller	Alderwoods: Out of the Woods The funeral provider offers a good investing lesson: Don't get too greedy. If you have a clear-cut list of reasons for selling the stock, then you have a better chance at ignoring the emotional whipsawing of the market.
The Motley Fool July 28, 2005 Rich Duprey	Chiron's Tragic Quarter The biotech vaccine maker barely breaks even but boasts of its ability to meet full-year expectations.
The Motley Fool April 29, 2005 Rex Moore	Why This Strategy Wins To envision big gains, investors need to think small.
The Motley Fool December 22, 2004 Tom Gardner	Finding Lynch's 10-Baggers Outlined in Peter Lynch's book, One Up on Wall Street, consider these primary principles of investing when building or fine-tuning your own stock portfolio.
The Motley Fool October 8, 2004 Rick Aristotle Munarriz	A Fool Looks Back Stern Means Sirius... Little Bunny Flu Flu... Wall-to-Wall-to-Wal-Mart... Two for the Show...
The Motley Fool December 8, 2004 Rich Smith	How to Turn $1,000 Into $1 Million There's no reason it can't happen for you. Save money. Invest it regularly. Let the magic of compounding returns work for you.
The Motley Fool January 5, 2005 Chuck Saletta	Sominex for Your Portfolio Investing is a risky activity. Make sure your stocks don't keep you up at night.
The Motley Fool February 9, 2005 Rich Smith	How to Turn $1,000 Into $1 Million There's no reason that it can't happen for you. Save money. Invest it regularly. Let the magic of compounding returns work for you.
The Motley Fool December 7, 2004 Brian Gorman	ID Biomedical's Shot in the Arm The company appears well-positioned for the coming years, but it may be best to stay cautious on the company.
The Motley Fool April 3, 2006 Nathan Parmelee	Alderwoods Passes On Death-care provider Alderwoods is snapped up by Service Corp. International. Since the share price is still a bit below the $20.00 per share being offered, it looks like the market agrees and isn't expecting a higher offer to come along.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool January 5, 2005	Recommended Reading Here are some books that can turbocharge your investing: The Motley Fool Rule Breakers, Rule Makers by David and Tom Gardner... The Wealthy Barber by David Chilton... One Up on Wall Street by Peter Lynch with John Rothchild... etc.
The Motley Fool January 16, 2007 Brian Lawler	MedImmune's Improved Flu Vaccine One of the three most important traits for a drug's success is convenience in dosing, so investors should be mindful of the FDA's actions on FluMist, MedImmune's nasal spray vaccine, in the coming months.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
The Motley Fool October 11, 2004 Richard Gibbons	4 Ways to Profit From Catastrophes What to do when bad news strikes a company you're watching.
The Motley Fool July 18, 2006 Ryan Fuhrmann	Bird Flu Planning Isn't for the Birds Buffalo Wild Wings discusses its strategy for dealing with the threat of avian flu. It's impossible to completely eliminate some risks, but it's quite possible for an astute firm to effectively manage any adversity that may come down its path. Investors, take note.
The Motley Fool March 3, 2005 Rich Duprey	Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief.
AskMen.com	1 Million Swine Flu Cases? Swine flu has infected as many as 1 million Americans, U.S. health officials said Thursday, adding that 6 percent or more of some urban populations are infected.
Search Engine Watch October 6, 2010 Matthew Ncube	Flu Search Query Trends in Google -- Paid Search Opportunity? Google is trying to get ready for the upcoming flu season, and in the process, it seems they've created a market for paid search traffic in the SERPs.
The Motley Fool October 30, 2006 Brian Lawler	MedImmune's Mediocre Quarter Some patient folks may be willing to wait on MedImmune to turn things around and justify its high valuation, but most other investors should be able to find better value elsewhere in the biotech industry.
American Family Physician January 15, 2004	Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc.
The Motley Fool May 17, 2007 Brian Lawler	MedImmune Gets the Thumbs-Up An advisory panel recommends expanded use for one of MedImmune's drugs.
The Motley Fool October 15, 2004 Tom Gardner	Save Your Portfolio Tired of watching your portfolio twist in the wind? One of the finest ways to preserve your capital over the long term is to keep investing it into stocks.